Lingxi Cloud Medical Technology

About Lingxi Cloud Medical Technology

Lingxi Cloud Medical Technology, also known as Lingxi Medical, operates at the intersection of artificial intelligence and neuroscience, developing a brain-computer interface (BCI) data platform for the diagnosis and treatment of brain disorders. The company was founded in 2019, emerging from two decades of research at Tsinghua University's Neuro-engineering Laboratory. It was co-founded by a team of distinguished scientists: international neuro-engineering expert Professor Hong Bo, neuroscientist Professor Lu Bai, and top AI scientist Dr. Hongjiang Zhang. The company is led by founder and CEO Yan Yuxiang. The firm's core business revolves around its proprietary "neurodynamics" large model, a sophisticated AI trained on extensive EEG data to provide biologically interpretable and quantitative assessments of brain function. This technology forms the basis of its main offering: an AI-powered brain function assessment system. The system significantly reduces the time for expert analysis of an EEG from hours to just minutes, generating a millimeter-level "brain function activity map" to precisely identify abnormal areas. This enables more accurate and efficient diagnosis and treatment planning for a range of neurological and psychiatric conditions.Lingxi Medical's business model targets three primary client segments: clinical departments in hospitals (neurology and psychiatry), pharmaceutical companies developing drugs for brain diseases, and primary care institutions involved in chronic disease management. The platform is designed to assist in the diagnosis of conditions such as epilepsy, depression, Alzheimer's disease, schizophrenia, and sleep disorders. The company has gained significant traction within China's healthcare system, with its diagnostic systems deployed in large hospitals across more than 20 provinces. To fuel its expansion and research, Lingxi Medical secured nearly CNY 100 million in a Series A funding round in early 2026, with the capital earmarked for advancing its BCI clinical data platform and pursuing regulatory approval for its core products.